Symbols

BMRN

Biomarin·NASDAQ

--(--)

BMRN fundamentals

BMRN Q4 2025 Earnings

Biomarin (BMRN) released its earnings on Feb 23, 2026: revenue was 874.57M (YoY +17.08%), beat estimates; EPS was -0.24 (YoY -137.50%), missed estimates.

Revenue / YoY

874.57M

+17.08%

EPS / YoY

-0.24

-137.50%

Report date

Feb 23, 2026

BMRN Earnings Call Summary for Q4,2025

Revenue Growth: 2025 total revenue $3.22 billion (+13% YoY), driven by 26% Voxzogo growth.
Strategic Expansion: $3.7 billion debt financing for Amicus acquisition, targeting 2030s growth.
Pipeline Momentum:
- BMN 333 Phase II/III to begin Q1 2026, targeting 2.25 cm/year growth.
- Voxzogo hypochondroplasia data expected H1 2026.
Financial Strength: 2026 non-GAAP EPS guidance $4.95-5.15, reflecting $0.25/share Amicus costs.
Market Leadership: 75% Voxzogo revenue outside U.S., focus on early diagnosis and underpenetrated markets.

Earnings

EPS

Revenue

Revenue & Expenses

BMRN has released its 2025 Q4 earnings report, with revenue of 874.57M, reflecting a YoY change of 17.03%, and net profit of -46.57M, showing a YoY change of -137.28%. The Sankey diagram below clearly presents BMRN's revenue sources and cost distribution.

Key Indicators

Biomarin (BMRN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Biomarin (BMRN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Biomarin (BMRN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Biomarin (BMRN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown